Approved HIV Medications

Non-Nucleoside Reverse Transcriptase Inhibitors NNRTIs in Development NNRTIs No Longer in Development

Note: Several fact sheets describe drugs that are being tested against HIV:

Fact Sheet 410: nucleoside analog reverse transcriptase inhibito...

Protease Inhibitors Protease Inhibitors in Development PIs No Longer in Development

NOTE: Several fact sheets describe drugs that are being tested against HIV:

Fact Sheet 410: nucleoside analog reverse transcriptase inhibitors (nukes) Fact ...

  Brand Name: AgeneraseCommon Name: amprenavirClass: HIV protease inhibitor (PI)Standard Dose: 1200 mg twice daily. The 150 mg soft gelatin capsules were taken off the market because of the new formulation (Lexiva), but the 50 mg capsule an...

A number of new drugs from existing classes are being studied. Here's a brief rundown of drugs that have started trials in people:

Nucleoside Analog Reverse Transcriptase Inhibitors (NRTIs)

Amdoxovir (DAPD): Early results from an ongoing Phase II s...

The 150-mg soft, gelatin capsule of Agenerase (shown) was large, cream-white, oblong, and imprinted with "GX CC2" on one side. However, beginning in 2005, the drug is only available in 50-mg capsules and as a flavored solution (mainly for pediatric u...

How do they work against the virus?

The non-nucleoside reverse transcriptase inhibitors (NNRTIs, also known as "non-nukes") are drugs that attach to the reverse transcriptase enzyme. They bind in a site that is somewhat different than the "nukes", b...

The backbone of antiretroviral therapy remains two nucleoside reverse transcriptase inhibitors (also called nucleosides or "nukes"), whether you are taking a non-nucleoside or protease inhibitor (Table 2: Antiretroviral Regimens Recommended for Treat...

Currently, there are eight approved compounds for the treatment of HIV infections that are in the class known as protease inhibitors. Of all classes of HIV medications, the protease inhibitors are the most complex in terms of pharmacokinetics, drug i...

Gilead Sciences, Inc., the manufacturer of the anti-HIV medication Tenofovir (Viread) today issued a "Dear Health Care Professional" letter (click here to view) describing high rates of virologic failure in patients treated with a "once-a-day" triple...

The original formulation of the protease inhibitor saquinavir -- Invirase -- became available in North America around the mid-1990s. However, Invirase was poorly absorbed. The manufacturer suggested that taking Invirase with concentrated grapefruit j...